Media stories about Sagent Pharmaceuticals (NASDAQ:SGNT) have been trending somewhat positive on Monday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sagent Pharmaceuticals earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.6737322921936 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.watchlistnews.com/sagent-pharmaceuticals-sgnt-earning-somewhat-positive-press-coverage-report-shows/1528360.html.

About Sagent Pharmaceuticals

Sagent Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market.

Receive News & Ratings for Sagent Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagent Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.